Serum B cell maturation antigen (BCMA) levels differentiate primary antibody deficiencies

Publication date: Available online 17 August 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Paul J. Maglione, Huaibin M. Ko, Minami Tokuyama, Gavin Gyimesi, Camilia Soof, Mingjie Li, Eric Sanchez, Haiming Chen, Lin Radigan, James Berenson, Charlotte Cunningham-RundlesABSTRACTBackgroundPrimary antibody deficiencies (PAD) are the most prevalent primary immunodeficiencies. More severe forms of PAD, common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA), require immunoglobulin replacement therapy (IRT) and may have serious complications. Differentiating severe PAD from milder hypogammaglobulinemia not requiring IRT can involve prolonged evaluations and treatment discontinuation. Severe PAD is defined by plasma cell deficiency, but this requires a biopsy to establish. Serum B cell maturation antigen (sBCMA) is elevated in multiple myeloma, but levels are reduced among myeloma patients in remission who have hypogammaglobulinemia.ObjectiveWe measured sBCMA levels in 165 subjects to determine whether it differentiates the severe PAD, CVID and XLA, from less severe forms not requiring IRT and those without PAD.Methods: sBCMA, B-cells, and tissue plasma cells were measured among subjects with and without PAD, and correlated to clinical and laboratory data.ResultsSubjects with IgG
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research

Related Links:

In what ways do the updated US and European guidelines on insect sting allergy differ?Current Opinion in Allergy and Clinical Immunology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Allergy & Clinical Immunology Journal Article Source Type: news
It seems like everyone leaping into healthcare these days. Black+Decker is the latest “unlikely player” to come to healthcare – and has developed a robot assistant to help adults and their caregivers independently and proactively manage their healthcare at home. Black+Decker, known mostly for its work on producing household appliances, teamed up with Pillo Health to develop the Pria robot assistant. Boston-based Pillo Health developed the proprietary technology platform that powers Pria, and Black+Decker is facilitating its direct launch to consumers. Towson, MD-based B...
Source: MDDI - Category: Medical Devices Authors: Tags: Digital Health Source Type: news
Source: Journal of Asthma and Allergy - Category: Allergy & Immunology Tags: Journal of Asthma and Allergy Source Type: research
Source: Journal of Asthma and Allergy - Category: Allergy & Immunology Tags: Journal of Asthma and Allergy Source Type: research
A 53-year-old woman with no significant medical history presented with nausea, vomiting, shortness of breath, epistaxis, unintentional 20-lb weight loss, and acute kidney injury with a creatinine level of 33.0 mg/dl, requiring hemodialysis. Physical examination was unremarkable. The radiographs revealed multiple lytic lesions of the hip and skull. Laboratory evaluation revealed a monoclonal serum spike, a serum free kappa to lambda light chain ratio of 0.002, a serum calcium level of 9.2 mg/dl, a hematocrit level of 22%, a platelet count of 160,000/ μl, and a white blood cell count of 8400/μl.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Make Your Diagnosis Source Type: research
For people with peanut allergies, new treatments in the pipeline offer the promise of tolerating small amounts of the same allergen that threatens them. A new study found clues about which patients may succeed on oral immunotherapy. Will patients find the trade-offs palatable?
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news
Conditions:   Multiple Myeloma;   Multiple Myeloma in Relapse Interventions:   Drug: Ixazomib;   Drug: Pomalidomide;   Drug: Dexamethasone Sponsors:   Paul G. Richardson, MD;   Takeda Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Glabellar Lines Interventions:   Drug: AGN-151586;   Drug: Placebo Sponsor:   Allergan Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Multiple Myeloma;   New Diagnosis Tumor Interventions:   Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Dexamethasone Sponsor:   Fondazione Neoplasie Sangue Onlus Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Glabellar Lines Interventions:   Drug: AGN-151586;   Drug: Placebo Sponsor:   Allergan Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Allergy | Allergy & Immunology | Gastroenterology | Laboratory Medicine | Myeloma | Primary Immunodeficiency Disease | Study | X-Linked Agammaglobulinemia (XLA)